Novacyt S.A. Director/PDMR Shareholding (9886N)

TIDMNCYT

RNS Number : 9886N

Novacyt S.A.

26 May 2020

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholdings

Paris, France and Camberley, UK - 26 May 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 May 2020, the following Director purchased ordinary shares of EUR1/15 each in the Company (the "Ordinary Shares"):

 
 Director       Title                    Number of      Price paid     Resultant      % of issued 
                                          Ordinary    per Ordinary    beneficial    share capital 
                                  Shares purchased           Share       holding 
 Jean-Pierre    Non Executive 
  Crinelli       Director                    5,899       EUR3.3781        21,232            0.03% 
               ---------------  ------------------  --------------  ------------  --------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name 
                                          Jean-Pierre Crinelli - Non 
                                          Executive Director 
     --------------------------------  ------------------------------- 
 2.   Reason for the Notification 
     ----------------------------------------------------------------- 
 a)   Position/status                   See 1(a) - classified as 
                                         a PDMR of the Company 
     --------------------------------  ------------------------------- 
 b)   Initial notification/ Amendment   Initial Notification 
     --------------------------------  ------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------- 
 a)   Name                              Novacyt S.A. 
     --------------------------------  ------------------------------- 
 b)   LEI                               213800BWAC2BF295EG28 
     --------------------------------  ------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------- 
 a)   Description of the Financial      ordinary shares of EUR1/15 
       instrument, type of instrument    each 
     --------------------------------  ------------------------------- 
      Identification code               FR0010397232 
     --------------------------------  ------------------------------- 
 b)   Nature of the transaction         Acquisition of Ordinary Shares 
     --------------------------------  ------------------------------- 
 c)   Price(s) and volume(s)                   Price       Volume 
                                                EUR3.3781   5,899 
                                                           ------- 
     --------------------------------  ------------------------------- 
 d)   Aggregated information: 
       -- Aggregated volume               N/A Single transaction as 
       -- Price                           above Price       Volume 
                                           EUR3.3781   5,899 
                                                      ------- 
     --------------------------------  ------------------------------- 
 e)   Date of the transaction 
                                          25 May 2020 
     --------------------------------  ------------------------------- 
 f)   Place of the transaction          Euronext Growth Paris 
     --------------------------------  ------------------------------- 
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

[phone]

[e-mail] / [e-mail]

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

   For more information please refer to the website:   www.novacyt.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHPPUCUAUPUGMQ

(END) Dow Jones Newswires

May 26, 2020 13:15 ET (17:15 GMT)